Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Phase 1 Completed 29 enrolled Vincerx Pharma, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer

Timeline

Start: 2023-01-24
Primary completion: 2024-10-10
Completion: 2024-10-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIP236	Unknown	—	Intravenous

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Summary

Timeline

Drugs

Indications